Icosavax, Inc.

NasdaqGS:ICVX Stock Report

Market Cap: US$777.8m

Icosavax Management

Management criteria checks 1/4

Icosavax's CEO is Adam Simpson, appointed in Dec 2017, has a tenure of 6.17 years. total yearly compensation is $6.91M, comprised of 8.4% salary and 91.6% bonuses, including company stock and options. directly owns 2.01% of the company’s shares, worth $15.66M. The average tenure of the management team and the board of directors is 1.9 years and 2.8 years respectively.

Key information

Adam Simpson

Chief executive officer

US$6.9m

Total compensation

CEO salary percentage8.4%
CEO tenure6.2yrs
CEO ownership2.0%
Management average tenure1.9yrs
Board average tenure2.8yrs

Recent management updates

Recent updates

We Think Icosavax (NASDAQ:ICVX) Can Afford To Drive Business Growth

Jul 04
We Think Icosavax (NASDAQ:ICVX) Can Afford To Drive Business Growth

Will Icosavax (NASDAQ:ICVX) Spend Its Cash Wisely?

Mar 10
Will Icosavax (NASDAQ:ICVX) Spend Its Cash Wisely?

Is Icosavax (NASDAQ:ICVX) In A Good Position To Invest In Growth?

Oct 18
Is Icosavax (NASDAQ:ICVX) In A Good Position To Invest In Growth?

Icosavax GAAP EPS of -$0.57

Aug 15

Icosavax to pursue COVID bivalent vaccine in 2023 as biotech highlights near-term milestones

Jul 28

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Jun 22
Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Mar 24
Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

We're Hopeful That Icosavax (NASDAQ:ICVX) Will Use Its Cash Wisely

Oct 29
We're Hopeful That Icosavax (NASDAQ:ICVX) Will Use Its Cash Wisely

CEO Compensation Analysis

How has Adam Simpson's remuneration changed compared to Icosavax's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2023n/an/a

-US$97m

Jun 30 2023n/an/a

-US$97m

Mar 31 2023n/an/a

-US$93m

Dec 31 2022US$7mUS$580k

-US$92m

Sep 30 2022n/an/a

-US$86m

Jun 30 2022n/an/a

-US$99m

Mar 31 2022n/an/a

-US$85m

Dec 31 2021US$18mUS$507k

-US$67m

Sep 30 2021n/an/a

-US$53m

Jun 30 2021n/an/a

-US$25m

Mar 31 2021n/an/a

-US$21m

Dec 31 2020US$623kUS$357k

-US$19m

Compensation vs Market: Adam's total compensation ($USD6.91M) is above average for companies of similar size in the US market ($USD3.31M).

Compensation vs Earnings: Adam's compensation has been consistent with company performance over the past year.

CEO

Adam Simpson (47 yo)

6.2yrs

Tenure

US$6,906,391

Compensation

Mr. Adam K. Simpson serves as President, Chief Executive Officer and Director of Icosavax, Inc. since December 2017 and also serves as its Co-Founder. Since 2012, Mr. Simpson has also served as the Preside...

Leadership Team

NamePositionTenureCompensationOwnership
Adam Simpson
President6.2yrsUS$6.91m2.01%
$ 15.7m
Niranjan Kanesa-thasan
Chief Medical Officer4.5yrsUS$2.22m0.37%
$ 2.9m
Cassia Cearley
Treasurer & Chief Business Officerno dataUS$2.38m0.20%
$ 1.5m
Neil King
Chair of Scientific Advisory Board & Co-Founderno datano datano data
David Baker
Co-founder & Member of Scientific Advisory Boardno datano datano data
Thomas Russo
Chief Financial Officer2.7yrsUS$5.76m0.017%
$ 130.2k
Jennifer Raymond
Senior Vice President of Technical Operations1.1yrsno datano data
Elizabeth Bekiroglu
General Counsel & Corporate Secretary2.4yrsUS$7.85m0.039%
$ 305.4k
Lori Stewart
Senior Vice President of People & Culture1.9yrsno datano data
Ami Brown
Senior Vice President of Regulatory Affairs1.9yrsno datano data
Amin Khan
Executive VP and Head of R&Dless than a yearno datano data
Antu Dey
Senior Vice President of Preclinical R&Dless than a yearno datano data

1.9yrs

Average Tenure

52yo

Average Age

Experienced Management: ICVX's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Adam Simpson
President6.2yrsUS$6.91m2.01%
$ 15.7m
Neil King
Chair of Scientific Advisory Board & Co-Founderno datano datano data
David Baker
Co-founder & Member of Scientific Advisory Boardno datano datano data
Mark McDade
Independent Chair4.5yrsUS$234.02k0.026%
$ 204.1k
Ann Veneman
Independent Director2.6yrsUS$184.71k0.0056%
$ 43.4k
Peter Kolchinsky
Independent Director2.9yrsUS$184.52kno data
Ralf Leo Clemens
Member of Scientific Advisory Boardno datano datano data
Robin Robinson
Member of Scientific Advisory Board2.1yrsno datano data
Jean-Paul Prieels
Member of Scientific Advisory Boardno datano datano data
Christian Mandl
Member of Scientific Advisory Boardno datano datano data
Barney Graham
Member of Scientific Advisory Boardno datano datano data
Heidi Kunz
Independent Director2.8yrsUS$196.52k0.0057%
$ 44.6k

2.8yrs

Average Tenure

67yo

Average Age

Experienced Board: ICVX's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/02/19 13:02
End of Day Share Price 2024/02/16 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Icosavax, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joshua SchimmerEvercore ISI
Seamus FernandezGuggenheim Securities, LLC
Roger SongJefferies LLC